Our Digital Content Producer, Paul Langley, talks with Race Oncology's CSO Dr Daniel Tillett, who explains how the recent clinical trials are evolving and what it means for the future. He gives a brief overview on the history of Race, their aspirations and milestones for development and eventual commercialisation of Zantrene.